Chordate Medical and Nanos Medical's joint venture Changyong Medical Technology Co. has submitted an application for product registration for the K.O.S treatment for chronic rhinitis in China.
“This is an important step towards market access in China. The next step in the project is entirely dependent on the answers we get from the Chinese supervisory authority's review work”, says Anders Weilandt, CEO of Chordate.
Chordate and Nanos Medical started a joint venture in 2018, forming the jointly owned company Changyong Medical Technology Co in Shanghai with the intention of marketing the K.O.S technology in the Chinese market. Nanos Medical owns two-thirds of this company and is the party that finances marketing and sales. Chordate owns the remaining third and will supply the Chinese patents when market authorization and product registration are in place.